Onkologie 2020: 14(Suppl.E): 106-111 | DOI: 10.36290/xon.2020.066

Male breast cancer

Jiří Gatěk1,2, Jiří Duben1, Bohumil Dudešek1, Martin Ratajský1, Pavel Holík2,3, Michaela Zábojníková4, David Vrána5
1 Chirurgické oddělení EUC klinika Zlín
2 Univerzita Tomáše Bati ve Zlíně
3 Knihovna, Univerzita Tomáše Bati ve Zlíně
4 Onkologické oddělení KTNB Zlín
5 Onkologické oddělení Nemocnice Nový Jičín

Male breast cancer is rare disease and it represents 1 % breast cancer. Invasive ductal cancer dominates in histology with 10 % portion in situ carcinoma. Other histology types are extraordinary. Female breast carcinoma has different diversion in molecular subtype than male carcinoma, which is predominant hormonal sensitive. Mastectomy is procedure of choice with sentinel node biopsy or axillary dissection in surgery. Radiotherapy is used after breast conservative procedure. Indication after mastectomy depends on stage of the carcinoma. Hormonal therapy is mainly applied in adjuvant therapy and mostly with Tamoxifen. Male carcinoma is very similar with female carcinoma but is not identical. Medical care come out from experience with treatment female carcinoma. Contemporary knowledge about male carcinoma needs new trials oriented on male carcinoma.

Keywords: male cancer, epidemiology, surgery, adjuvant therapy.

Published: September 25, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Gatěk J, Duben J, Dudešek B, Ratajský M, Holík P, Zábojníková M, Vrána D. Male breast cancer. Onkologie. 2020;14(Suppl.E / Onkologické kazuistiky 4):106-111. doi: 10.36290/xon.2020.066.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Javidiparsijani S, Rosen LE, Gattiso P. Male Breast Carcinoma: A Clinical and Pathological Review. International Journal of Surgical Pathology 2017; (23): 200-205 doi.org/10.1177/1066896916675953. Go to original source... Go to PubMed...
    2. Giordano SH. N Engl J Med. Breast Cancer in Men. 2018; (378): 2311-2320. doi: 10.1056/NEJMra1707939. Go to original source... Go to PubMed...
    3. Korde LA, Zujewski A, Kamin L, et al. Multidisciplinary Meeting on Male Breast Cancer: Summary and Research Recommendations. J Clin Oncol. 2010; (28): 2114-2122. doi: 10.1200/JCO.2009.25.5729. Go to original source... Go to PubMed...
    4. Bielčíková Z. Karcinom prsu u mužů. Onkologie. 2016; (10): 170-174. Go to original source...
    5. Weiss JR, Moysich, Swede H. Epidemiology of Male Breast Cancer. Cancer epidemiol Biomarkers Prev 2005; (14): 20-26. Go to original source... Go to PubMed...
    6. Abdelwahab Yousef AJ. Male Breast Cancer: Epidemiology and Risk Factors. Semin Oncol 2017; (44): 267-272. doi: 10.1053/j.seminoncol.2017.11.002. Go to original source... Go to PubMed...
    7. Ying WL, Agrawal A, Cheung KL. The 'other half' of breast cancer: A review of male breast cancer. The Journal of Men's Health & Gender 2005; (2): 406-413 https://doi.org/10.1016/j.jmhg.2005.10.012. Go to original source...
    8. Leon-Ferre RA, Giridhar KV, Hieken TJ, et al. A contemporary review of male breast cancer: current evidence and unanswered questions. Cancer Metastasis Rev. 2018; (37): 599-614. doi: 10.1007/s10555-018-9761-x. Go to original source... Go to PubMed...
    9. Coopey SB, Kartal K, Li C, et al. Atypical ductal hyperplasia in men with gynecomastia: what is their breast cancer risk? Breast Cancer Res Treat. 2019; (175): 1-4. doi: 10.1007/s10549-018-05117-4. Go to original source... Go to PubMed...
    10. Krause W. Male breast cancer-an andrological disease: risk factors and diagnosis. Andrologie 2004; (36): 346-354. Go to original source... Go to PubMed...
    11. Giordano SH, Perkins GH, Broglio K et al Adjuvant systemic therapy for male breast carcinoma. Cancer. 2005; (104): 2359-2364. Go to original source... Go to PubMed...
    12. Senger JL, Adams SJ, Rani KanthanR et al. Invasive lobular carcinoma of the male breast - a systematic review with an illustrative case study Breast Cancer 2017; (9): 337-345. doi: 10.2147/BCTT.S126341. Go to original source... Go to PubMed...
    13. Adams SJ, Kanthan R. Paget's disease of the male breast in the 21st century: A systematic review. Breast. 2016; (29): 14-23. doi: 10.1016/j.breast.2016.06.015. Go to original source... Go to PubMed...
    14. Gucalp A, Traina TA, Eisner JR, et al. Male breast cancer: a disease distinct from female breast cancer. Breast Cancer Res Treat. 2019; (173): 37-48. doi: 10.1007/s10549-018-4921-9. Go to original source... Go to PubMed...
    15. Johansson, Nilsson C, Berglund P, et al. Gene expression profiling of primary male breast cancers reveals two unique subgroups and identifies N-acetyltransferase-1 (NAT1) as a novel prognostic biomarker. Breast Cancer Research. 2012; (14): R31. Go to original source... Go to PubMed...
    16. Johansson Nilsson C, Berglund P, et al. High-resolution genomic profiling of male breast cancer reveals differences hidden behind the similar with female breast cancer. Breast Res Treat 2011; (3): 747-760. Go to original source... Go to PubMed...
    17. Vermeulen MA, Slaets L, Cardoso F, et al. Pathological characterisation of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Eur J Cancer. 2017; (82): 219-227. doi: 10.1016/j.ejca.2017.01.034. Go to original source... Go to PubMed...
    18. Cardoso F, Bartlett JMS, Slaets L, et al, Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Ann Oncol. 2018; (29): 405-417. doi: 10.1093/annonc/mdx651. Go to original source... Go to PubMed...
    19. Vincent F. Guinee VF, Shallenberger RC, Olsson H. The prognosis of breast cancer in males a report of 335 cases Cancer. 1993; (71): 154-161. https://doi.org/10.1002/1097-0142(19930101)71:1,154::AID-CNCR2820710125>3.0.CO;2-%23. Go to original source...
    20. Scheike O. Male breast cancer. 5. Clinical manifestations in 257 cases in Denmark Br J Cancer. 1973; (28): 552-561. Go to original source... Go to PubMed...
    21. Cloyd JM, Hernandez-Boussard T, Wapnir IL et al. Outcomes of partial mastectomy in male breast cancer patients: analysis of SEER, 1983-2009. Ann Surg Oncol. 2013; (20): 1545-1550. doi: 10.1245/s10434-013-2918-5. Go to original source... Go to PubMed...
    22. Leone J, Zwenger AO. Locoregional treatment and overall survival of men with T1a,b,cN0M0 breast cancer: A population-based study. Eur J Cancer. 2017; (71): 7-14. doi: 10.1016/j.ejca.2016.10.038. Go to original source... Go to PubMed...
    23. De La Cruz LM, Thiruchelvam TR, Shivani J. Saving the Male Breast: A Systematic Literature Review of Breast-Conservation Surgery for Male Breast Cancer. Annals of Surgical Oncology 2019; (26): 3939-3944. Go to original source... Go to PubMed...
    24. Reyal F, Rouzier R, Depont-Hazelzet B, et al. The molecular subtype classification is a determinant of sentinel node positivity in early breast carcinoma. PLoS One. 2011; (6): e20297. doi: 10.1371/journal.pone.0020297. Go to original source... Go to PubMed...
    25. Bevilacqua JL, Kattan MW, Fey JV, et al. Doctor, what are my chances of having a positive sentinel node? A validated nomogram for risk estimation. J Clin Oncol. 2007; (20): 3670-3679. Go to original source... Go to PubMed...
    26. Banys-Paluchowski M, Burandt E, Banys J, et al. Male papillary breast cancer treated by wide resection and latissimus dorsi flap reconstruction: A case report and review of the literature. World J Clin Oncol. 2016; (10): 420-424. Go to original source... Go to PubMed...
    27. Spear SL, Bowen DG. Breast reconstruction in a male with a transverse rectus abdominis flap. Plast Reconstr Surg. 1998; (102): 1615-1617. Go to original source... Go to PubMed...
    28. Fentiman IS Surgical options for male breast cancer. Breast Cancer Res Treat. 2018; (172): 539-544. doi: 10.1007/s10549-018-4952-2. Go to original source... Go to PubMed...
    29. Shak S, Palmer G, Baehner FL, et al Molecular characterization of male breast cancer by standardized quantitative RT-PCR analysis: First large genomic study of 347 male breast cancers compared to 82,434 female breast cancers. Journal of Clinical Oncology 2009; 27(Suppl. 15): 549-549. doi: 10.1200/jco.2009.27.15_suppl.549. Go to original source...
    30. Massarweh SA, Sledge GW, Miller DP, et al. Molecular Characterization and Mortality From Breast Cancer in Men. J Clin Oncol. 2018; (36): 1396-1404. doi: 10.1200/JCO.2017.76.8861 Go to original source... Go to PubMed...
    31. Abrams MJ, Koffer PP, Wazer DE, et al. Postmastectomy Radiation Therapy Is Associated With Improved Survival in Node-Positive Male Breast Cancer: A Population Analysis. Int J Radiat Oncol Biol Phys. 2017; (98): 384-391. doi: 10.1016/j.ijrobp.2017.02.007. Go to original source... Go to PubMed...
    32. Recht A, Comen EA, Fine RE, et al. Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update. Pract Radiat Oncol. 2016; (6): 219-e234. doi: 10.1016/j.prro.2016.08.009. Go to original source... Go to PubMed...
    33. Xu S, Yang Y, Tao W, et al. Tamoxifen adherence and its relationship to mortality in 116 men with breast cancer. Breast Cancer Res Treat. 2012; (136): 495-502. doi: 10.1007/s10549-012-2286-z. Go to original source... Go to PubMed...
    34. Eggemann H, Ignatov A, Smith BJ, et al. Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients. Breast Cancer Res Treat. 2013; (137) :465-470. doi: 10.1007/s10549-012-2355-3. Go to original source... Go to PubMed...
    35. Bezwoda W, Hesdorffer C, Dansey R, et al. Breast cancer in men. Clinical features, hormone receptor status, and response to therapy Cancer 1987; (60): 1337-1340. https://doi.org/10.1002/1097-0142(19870915)60:63.0.CO;2-C. Go to original source...
    36. Masci G, Gandini C, Zuradelli M, et al. Fulvestrant for advanced male breast cancer patients: a case series. Ann Oncol. 2011; (22): 985. doi: 10.1093/annonc/mdr005. Go to original source... Go to PubMed...
    37. Patel HZ, Buzdar AU, Hortobagyi GN. Role of adjuvant chemotherapy in male breast cancer. Cancer. 1989; (15): 1583-5 Go to original source...
    38. Cardoso F, Costa A, Senkus E, et al. International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Ann Oncol. 2017; 28(1): 16-33. doi: 10.1093/annonc/mdw544.3rd ESO-ESMO. Go to original source...
    39. Zagouri F, Sergentanis TN, Chrysikos D, et al. Fulvestrant and male breast cancer: a pooled analysis. Breast Cancer Res Treat. 2015; (149): 269-75. doi: 10.1007/s10549-014-3240-z. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.